title: Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
abstract: The aim of this study was to evaluate the effectiveness of the administration of the 7-valent pneumococcal conjugate vaccine in a region with an intermediate vaccination coverage. A matched case-control study was carried out in children aged 7-59 months with invasive pneumococcal disease (IPD) admitted to two university hospitals in Catalonia. Three controls matched for hospital, age, sex, date of hospitalization and underlying disease were selected for each case. Information on the vaccination status of cases and controls was obtained from the vaccination card, the child's health card, the hospital medical record or the vaccination register of the primary healthcare center where the child was attended for non-severe conditions. A conditional logistic regression analysis was made to control for the effect of possible confounding variables. The adjusted vaccination effectiveness of the complete vaccination schedule (3 doses at 2, 4 and 6 months and a fourth dose at 15 months, 2 doses at least two months apart in children aged 12-23 months or a single dose in children aged >24 months) in preventing IPD caused by vaccine serotypes was 93.7% (95% CI 51.8-99.2). It was not effective in preventing cases caused by non-vaccine serotypes. The results of this study carried out in a population with intermediate vaccination coverage confirm those of other observational studies showing high levels of effectiveness of routine 7-valent pneumococcal conjugate vaccination.
authors.affiliation: Departament de Salut Pública, Universitat de Barcelona, Barcelona, Spain. angela.dominguez@ub.edu
authors.forename: Angela
authors.initials: A
authors.lastname: Domínguez
authors.forename: Pilar
authors.initials: P
authors.lastname: Ciruela
authors.forename: Juan José
authors.initials: JJ
authors.lastname: García-García
authors.forename: Fernando
authors.initials: F
authors.lastname: Moraga
authors.forename: Mariona F
authors.initials: MF
authors.lastname: de Sevilla
authors.forename: Laura
authors.initials: L
authors.lastname: Selva
authors.forename: Francis
authors.initials: F
authors.lastname: Coll
authors.forename: Carmen
authors.initials: C
authors.lastname: Muñoz-Almagro
authors.forename: Ana María
authors.initials: AM
authors.lastname: Planes
authors.forename: Gemma
authors.initials: G
authors.lastname: Codina
authors.forename: Iolanda
authors.initials: I
authors.lastname: Jordán
authors.forename: Cristina
authors.initials: C
authors.lastname: Esteva
authors.forename: Sergi
authors.initials: S
authors.lastname: Hernández
authors.forename: Núria
authors.initials: N
authors.lastname: Soldevila
authors.forename: Neus
authors.initials: N
authors.lastname: Cardeñosa
authors.forename: Joan
authors.initials: J
authors.lastname: Batalla
authors.forename: Luis
authors.initials: L
authors.lastname: Salleras
mesh_terms: D016022:Case-Control Studies; D002675:Child, Preschool; D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D016015:Logistic Models; D008297:Male; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011159:Population Surveillance; D013030:Spain; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate